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Abstract 
Background: Silver nanoparticles (AgNPs) are potential antimicrobials agents, which can be considered as an alter‑
native to antibiotics for the treatment of infections caused by multi‑drug resistant bacteria. The antimicrobial effects 
of double and triple combinations of AgNPs, visible blue light, and the conventional antibiotics amoxicillin, azithromy‑
cin, clarithromycin, linezolid, and vancomycin, against ten clinical isolates of methicillin‑resistant Staphylococcus aureus 
(MRSA) were investigated.
Methods: The antimicrobial activity of AgNPs, applied in combination with blue light, against selected isolates of 
MRSA was investigated at 1/2–1/128 of its minimal inhibitory concentration (MIC) in 24‑well plates. The wells were 
exposed to blue light source at 460 nm and 250 mW for 1 h using a photon emitting diode. Samples were taken at 
different time intervals, and viable bacterial counts were determined. The double combinations of AgNPs and each 
of the antibiotics were assessed by the checkerboard method. The killing assay was used to test possible synergistic 
effects when blue light was further combined to AgNPs and each antibiotic at a time against selected isolates of 
MRSA.
Results: The bactericidal activity of AgNPs, at sub‑MIC, and blue light was significantly (p < 0.001) enhanced when 
both agents were applied in combination compared to each agent alone. Similarly, synergistic interactions were 
observed when AgNPs were combined with amoxicillin, azithromycin, clarithromycin or linezolid in 30–40 % of the 
double combinations with no observed antagonistic interaction against the tested isolates. Combination of the 
AgNPs with vancomycin did not result in enhanced killing against all isolates tested. The antimicrobial activity against 
MRSA isolates was significantly enhanced in triple combinations of AgNPs, blue light and antibiotic, compared to 
treatments involving one or two agents. The bactericidal activities were highest when azithromycin or clarithromycin 
was included in the triple therapy compared to the other antibiotics tested.
Conclusions: A new strategy can be used to combat serious infections caused by MRSA by combining AgNPs, blue 
light, and antibiotics. This triple therapy may include antibiotics, which have been proven to be ineffective against 
MRSA. The suggested approach would be useful to face the fast‑growing drug‑resistance with the slow development 
of new antimicrobial agents, and to preserve last resort antibiotics such as vancomycin.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
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Background
Treatment of infections caused by Staphylococcus aureus 
has become more difficult because of the emergence of 
multidrug-resistant isolates [1, 2]. Methicillin-resistant 
S. aureus (MRSA) presents problems for patients and 
healthcare facility-staff whose immune system is com-
promised, or who have open access to their bodies via 
wounds, catheters or drips. The infection spectrum 
ranges from superficial skin infections to more serious 
diseases such as bronchopneumonia [3].
Failure of antibiotics to manage infections caused by 
multidrug-resistant (MDR) pathogens, especially MRSA, 
has triggered much research effort for finding alternative 
antimicrobial approaches with higher efficiency and less 
resistance developed by the microorganisms. Silver has 
long been known to exhibit antimicrobial activity against 
wide range of microorganisms and has demonstrated 
considerable effectiveness in bactericidal applications [4] 
and silver nanoparticles (AgNPs) have been reconsidered 
as a potential alternative to conventional antimicrobial 
agents [5].
It has been estimated that 320 tons of nanosilver are 
used annually [6] with 30  % of all currently registered 
nano-products contain nanosilver [7]. The use of AgNPs 
alone or in combination with other antimicrobial agents 
has been suggested as a potential alternative for tradi-
tional treatment of infections caused by MDR pathogens 
[5]. AgNPs were found to exhibit antibacterial activity 
against MRSA in vitro when tested alone or in combina-
tion with other antimicrobial agents [8–10].
Metal nanostructures attract a lot of attention due to 
their unique properties. AgNPs is a potential biocide that 
has been reported to be less toxic compared to Silver 
ions [11]. AgNPs can be incorporated into antimicrobial 
applications such as bandages, surface coatings, medical 
equipment, food packaging, functional clothes and cos-
metics [12].
Blue light is recently attracting increasing attention as 
a novel phototherapy-based antimicrobial agent that has 
significant antimicrobial activity against a broad range 
of bacterial and fungal pathogens with less chance to 
resistance development compared to antibiotics [13, 14]. 
Further, blue light has been shown to be highly effective 
against MRSA and other common nosocomial bacterial 
pathogens [15, 16].
The present investigation aims to evaluate the effec-
tiveness of triple combination of AgNPs, blue light and 
the conventional antibiotics vancomycin, linezolid, 
amoxicillin, azithromycin, and clarithromycin against 
clinical isolates of MRSA. To the best of our knowledge, 
this is the first study, which utilizes this triple combina-
tion against pathogenic bacteria.
Methods
Chemicals
Unless otherwise indicated all chemicals were purchased 
from Sigma-Aldrich, USA.
Antibiotics
Amoxicillin (AMX), oxacillin (OXA), vancomycin (VAN) 
were purchased from Sigma Chemical Co., ST. Louis, 
Missouri, USA. Linezolid (LNZ) was provided by Phar-
macia & Upjohn, Kalamazoo, MI, USA. Azithromycin 
(AZM) was provided by Pfizer, USA. Clarithromycin 
(CLR) was provided by Abbott Laboratories, USA.
Microorganisms
Ten clinical MRSA isolates were collected from The 
National Cancer Institute and from Abbasseya Hospi-
tal in Cairo, Egypt. The collected isolates were identified 
using conventional microbiological techniques.
According to genotyping results, the isolates were 
sub-classified into 14 different pulsed field patterns, 11 
spa-types and 8 multiple locus sequence typing (MLST) 
sequence types. The pulsed field type A was the predomi-
nant pulsed field type, which corresponded to spa-type 
t-037 and MLST sequence type ST-239, and belonged to 
clonal complex 8 (CC8) according to eBURST analysis 
(Table 1) (Unpublished data, Master Thesis, Moussa et al. 
2010).
Oxacillin susceptibility
The isolates were inoculated onto Mueller–Hinton agar 
(Lab M, UK) plates supplemented with 4  % NaCl and 
6  µg/mL oxacillin, followed by incubation at 37  °C for 
24  h. Isolates that showed more than one colony were 
considered as MRSA [17].
Preparation of the AgNPs
The AgNPs used for the purpose of this research are 
silver magnetite nanoparticles. To prepare the AgNPs, 
0.127 g silver nitrate were dissolved in 75 mL of distilled 
water then 10  mL of an aqueous solution containing 
0.08  g trisodium citrate and 0.2  g polyvinylpyrrolidone 
(PVP) were added. Ten milliliter of 0.1 M sodium boro-
hydride were dissolved and added to the mixture. The 
Keywords: Nonconventional antimicrobials, Double and triple combinations, Multidrug‑resistance, Checkerboard 
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solution turned dark brown indicating the conversion of 
silver nitrate to silver nanoparticles. The nanoparticles 
were characterized spectrophotometrically, where a sur-
face plasmon resonance peak appeared between 390 and 
410 nm [18]. The particles size was also characterized by 
Malvern Zetasizer Nano ZS (United Kingdom) and by 
Tecnai G20, Super twin, double tilt (FEI) ultra-high reso-
lution Transmission Electron Microscope, which showed 
a uniform distribution of the nanoparticles, with an aver-
age size of 15–20 nm.
Susceptibility of the isolates to AgNPs and the antibiotics
MIC of the AgNPs was determined by the broth micro-
dilution method using cation-adjusted Mueller–Hin-
ton broth (MHB) based on the guidelines of the Clinical 
Laboratory Standard Institute (CLSI) [19]. The minimum 
bactericidal concentration (MBC) was determined by 
streaking 10  µL samples from bacterial cultures sup-
plemented with AgNPs or the antibiotics at their MICs 
and higher concentrations, onto the surfaces of Muller 
Hinton agar plates. After a 24  h incubation period, the 
number of colony forming units per mL (CFU/mL) was 
determined and the MBC, defined as the concentration 
that kills 99.9 % of bacteria, was recorded.
Double combination of AgNPs with blue light 
against MRSA
AgNPs were tested at 1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and 
1/128 of its MIC in 24-wells plates. Briefly, bacterial sus-
pensions were pipetted into the wells, which contained 
the AgNPs at the tested concentrations in MHB to give 
an initial inoculum size of 1 ×  105 CFU/mL and a final 
volume of 2  mL/well. The wells were exposed to visible 
blue light source at 460  nm and 250  mW for 1  h using 
Photon Emitting Diode (Photon Scientific, Egypt). Sam-
ples were taken after 0, 2, 4, 6, 8 and 10 h of inoculation, 
where viable bacterial counts were determined. Briefly, 
10  µL aliquots were withdrawn and spread onto nutri-
ent agar plates before being incubated at 37 °C for 24 h. 
The same procedure was repeated with nanoparticles-
free and light-free wells. The experiment was performed 
in triplicates and the results were compared to drug-free 
samples.
Double combination of AgNPs with the antibiotics 
against MRSA
The efficiency of double combination of AgNPs and 
amoxicillin, vancomycin, linezolid, azithromycin, or 
clarithromycin against the ten clinical isolates of MRSA 
was assessed by the checkerboard method. The combina-
tion response was evaluated by calculation of the Frac-
tion Inhibitory Index (∑ FIC) as follow:
The interaction is defined as synergistic if the FIC index 
is 0.5 or less; indifferent, if the FIC index is >0.5 and <4; 
and antagonistic if the FIC index is >4 [20].
Triple combination of AgNPs, blue light, and the antibiotics 
against MRSA
The purpose of this experiment was to test the effective-
ness of AgNPs in combination with blue light and each 
of the following antibiotics at a time: amoxicillin, vanco-
mycin, linezolid, azithromycin, or clarithromycin, against 
selected isolates of MRSA. Two isolates from the combi-
nation of AgNPs and each of the tested antibiotics were 
chosen on the basis of the synergistic response in the 
checkerboard assay.
The experiments were carried out in 24 multi-well 
plates where eight wells were designated as: drug- and 
light-free, blue light exposure, AgNPs alone, the antibi-
otic alone, blue light and AgNPs, blue light and the anti-
biotic, AgNPs and the antibiotic, and finally, the triple 
combination blue light, AgNPs and the antibiotic. The 24 
multi-well plates were used because the diameter of their 
wells fits the tip of the Photon Emitting Diode, where 
the diode was placed at a distance of 5 mm over the sur-
face of the bacterial culture in the well to ensure optimal 
exposure to the light and reduce light scattering. Only the 
wells in the four corners of one plate were used in paral-
lel treatments to avoid the scattered light from adjacent 
wells, if any; all other wells were left empty.
The AgNPs and the antibiotics were tested at concen-
trations that resulted in the best combination in check-
erboard assay against the selected isolates. Bacterial 
∑
FIC =
MIC of drug A, in combination
MIC of drugA, tested along
+
MIC of drug B, in combination
MIC of drug B, tested along




Spa-repeats MLST Clonal complex 
(eBURST)
SCCmec
C51 t‑186 ST‑88 CC88 IIIa
C6 t‑5711 ST‑22 CC22 IVa
C43 t‑037 ST‑239 CC8 III
N11 t‑363 ST‑239 CC8 III
N5 t‑037 ST‑239 CC8 III
N8 t‑037 ST‑239 CC8 III
C34 t‑037 ST‑239 CC8 III
C19 t‑037 ST‑239 CC8 III
C12 t‑037 ST‑239 CC8 III
C41 t‑1234 ST‑97 CC97 III
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suspensions were pipetted into the wells, which con-
tained the AgNPs alone or in combination with the anti-
biotics at the test concentrations in MHB to give an initial 
inoculum size of 1 × 105 CFU/mL and a final volume of 
2 mL/well. The wells designated for light treatment were 
exposed to the light source emitting blue light at a wave-
length of 460 nm for 1 h. The plates were then incubated 
at 37 °C for 24 h after which viable cell counts were deter-
mined. The experiment was performed in triplicate, and 
the results obtained were compared to the drug- and blue 
light-free wells.
Effects of triple combination of AgNPs, blue light, 
and azithromycin on MRSA isolate using transmission 
electron microscopy (TEM)
Ten milliliter of MHB medium were inoculated with 
1 × 105 CFU/mL of MRSA isolate (N8) in 15 mL coni-
cal centrifuge tubes (Falcon, USA). The suspensions 
were then incubated at 37  °C for 4  h till the bacteria 
reached the logarithmic phase. The suspensions were 
then centrifuged at 2800×g for 10 min and the cell pel-
lets were re-suspended in 10 mL of the fresh drug-free 
MHB, or containing 0.25 µg/mL (1/16 MIC) of AgNPs, 
or 0.25  µg/mL of azithromycin or both agents. Two 
milliliter aliquots of the suspension were transferred 
to 24 multi-wells plates. The plates were incubated at 
room temperature during which the blue light wells 
were exposed to the light at 460 nm for 1 h. One mil-
liliter samples were then taken and prepared for TEM 
as previously described [21]. Briefly, the samples were 
centrifuged, and the bacterial pellets were fixed in 
1  mL of 3  % glutaraldehyde for 2  h and then centri-
fuged and washed with 7.2 % phosphate buffer. A sec-
ondary fixative, osmium tetraoxide, was then added 
to the pellets, incubated for 1  h before being washed 
with phosphate buffer saline. The samples were then 
subjected to a series of dehydration steps using differ-
ent concentrations of ethanol, starting with ethanol 
50–95  %. During each step, the samples were left for 
10  min and then put in absolute ethanol for 20  min. 
The samples were then embedded in resin blocks that 
were subsequently cut into semi- then ultra-thin thick-
ness and finally stained with uranyl acetate and lead 
citrate before being examined by TEM JEOL (JEM-
1400). The results were compared to drug- and light-
free control experiments.
Statistical analysis
The statistical analysis of the data was done using Graph-
Pad Prism (version 5.0) software. One-way- and two-
way analysis of variance (ANOVA) were used to test the 
significance among the different treatment groups, and 
5 % error was accepted in the statistics. Error bars in the 
graphical presentation of data express the standard devi-
ation of the means between samples.
Results
Susceptibility of the isolates to AgNPs and the antibiotics
The MIC of AgNPs was found to be 4 µg/mL with MBC 
range of 8–16  µg/mL, and MBC90 (The minimum bac-
tericidal concentration of the antibiotic required to 
kill 99.9 % of bacteria in 90 % of the isolates) was 8 µg/
mL (Table  2). Vancomycin is the only antibiotic, which 
showed activity against the tested isolates with MIC90 
(the minimum inhibitory concentration of the antibi-
otic required to inhibit the growth of 90  % of the iso-
lates) and MBC90 values of 2 and 8  µg/mL, respectively 
(Table  2). The isolates were resistant to linezolid with 
MIC90 of 32 µg/mL, and to amoxicillin, azithromycin and 
clarithromycin with MIC90 >64 µg/mL.
Combination of AgNPs with blue light against MRSA
The antimicrobial activity of AgNPs in combination with 
blue light against one of the MRSA isolates was investi-
gated. The AgNPs were tested at 1/2, 1/4, 1/8, 1/16, 1/32, 
1/64 and 1/128 of its MIC in 24-wells plates. The antimi-
crobial activity of these combinations against the tested 
isolate was significantly higher (p  <  0.001) than each 
agent alone. All bacteria were killed after 8 h of exposure 
to the combined therapy at all tested concentrations. Fig-
ure 1 shows the results for the combinations tested at 1/2, 
1/4, 1/8, and 1/16 of the MIC of AgNPs (data for lower 
concentrations are not shown).
Combination of AgNPs with the antibiotics against MRSA
The efficiency of the double combination of the AgNPs 
and each of amoxicillin, vancomycin, linezolid, azithro-
mycin, or clarithromycin, against the ten clinical MRSA 
isolates was assessed using the checkerboard method. The 
Table 2 Susceptibility of  the tested isolates to  AgNPs 
and the antibiotics
a MIC90: The minimum inhibitory concentration of the antibiotic required to 
inhibit the growth of 90 % of the isolates. MBC90: The minimum bactericidal 
concentration of the antibiotic required to kill 99.9 % of bacteria in 90 % of the 
isolates
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combination of AgNPs with amoxicillin resulted in syn-
ergistic activity against four isolates whereas indifference 
response was observed in six isolates. Similar results were 
observed when the AgNPs were combined with azithro-
mycin, clarithromycin or linezolid, where synergism was 
observed against 4, 3 and 3 isolates, respectively, whereas 
indifferent interaction prevailed for the remaining iso-
lates. On the other hand, combination of AgNPs with van-
comycin was indifferent for all tested isolates (Fig. 2).
Triple combination of AgNPs, blue light, and the antibiotics 
against MRSA isolates
The effectiveness of the AgNPs in combination with blue 
light and amoxicillin, linezolid, azithromycin, or clarithro-
mycin, was tested against selected isolates of MRSA. Two 
isolates from each combination of AgNPs and antibiotic 
were selected based on the synergistic results of the check-
erboard assay. Vancomycin was excluded because its com-
bination with the AgNPs was indifferent against all isolates.
a b
c d
Fig. 1 Antimicrobial activity of the AgNPs at different concentrations in combination with blue light against MRSA isolates. Cell suspensions were 
exposed to either the silver compound alone at sub‑MICs (a 1/2, b 1/4, c 1/8, and d 1/16 MIC), or blue light alone at 460 nm and 250 mW for 1 h, or 
combination of both agents. Viable colony count was recorded as mean ± SD of three independent experiments. AgNPs silver nanoparticles, CFU 
colony forming unit, MIC minimum inhibitory concentration, SD standard deviation
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The AgNPs and the antibiotics were tested at the con-
centrations, which gave the best results in checkerboard 
assay. Isolates N8 and C41 were used to assess the triple 
combination of AgNPs at 1/16 MIC, the blue light, and 
azithromycin at 0.25 and 2 µg/mL, respectively. The triple 
combination resulted in significantly higher (p  <  0.001) 
killing effect of isolate C41 with log10 CFU/mL reduc-
tions of 8.4, 3.2, compared to the drug-free samples and 
to the double combinations of the antibiotic with the 
AgNPs (Fig.  3a). The triple combinations against isolate 
N8 resulted in killing of all bacteria compared to all other 
treatments, which showed lower activity with log10 CFU/
mL reduction range of 1.0–2.0 (Fig. 3b).
Triple combinations that included clarithromycin were 
tested against isolates C51 and C41, at 1/8 and 1/512 of 
the MIC, respectively, of the AgNPs and 0.25  µg/mL of 
the antibiotic. The bactericidal activity of the three-agent 
combination was significantly higher (p  <  0.001) than 
that attained with other treatment combinations with 
log10 CFU/mL reduction of 13.02 and 5.84 compared to 
the control of the two isolates, respectively (Fig. 4a, b).
The antimicrobial efficacy of linezolid at 0.25 and 8 µg/
mL was evaluated against isolate C19 and N5, respec-
tively, when combined with the silver compound at 
its 1/2 MIC and blue light. Synergistic interaction was 
observed when the AgNPs were combined with either the 
antibiotic or the blue light or with both of them, where 
the bacteria were completely killed following treatment 
with all combinations (Fig.  5a, b). The same effect was 
observed when amoxicillin at 1 and 0.25 µg/mL was com-
bined with blue light and AgNPs at 1/32 and 1/256 of its 
MIC against isolates C12 and N8, respectively (data not 
shown).
TEM examination of MRSA isolate (N8) after treatment 
with the AgNPs, blue light, and azithromycin alone or 
in triple combination
The antimicrobial efficiency of the AgNPs at 1/16 MIC, 
blue light for 1 h and azithromycin at 0.25 µg/mL against 
isolate N8 was visualized by TEM when each of them was 
used alone or in triple combination (Fig. 6a–e). Bacteria 
treated with AgNPs alone showed accumulation of the 
silver particles inside the cells concomitant with signs 
of membrane damage and lysis (Fig.  6b). Cell lysis was 
also observed when the bacteria were treated with either 
blue light or azithromycin alone (Fig. 6c, d). On the other 
hand, bacterial cell lysis was more pronounced following 
treatment with the three agents in combination, where 
the cells were severely affected (Fig. 6e).
Discussion
Antibiotic resistance by isolates of S. aureus has become 
a global alarming problem that limits the availability of 
effective antimicrobial agents [22]. Antibiotic-misuse, 
the failure of some patients to comply with their treat-
ment regimen, and the high capability of bacteria to 
Fig. 2 Double combination of AgNPs with the amoxicillin, vancomycin, linezolid, azithromycin or clarithromycin against ten MRSA isolates. The 
combination was assessed by the checkerboard method and the response was evaluated by calculation of the fraction inhibitory index (FIC) as 
follow: synergistic if the FIC index is 0.5 or less, indifference if the FIC index more than 0.5 and less than four, and antagonistic if the FIC index more 
than four. AgNPs silver nanoparticles, AMX amoxicillin, AZM azithromycin, CLR clarithromycin, LNZ linezolid, VAN vancomycin
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mutate, are among the major factors contributing to 
the emergence of bacterial resistance. Antibiotic resist-
ance leads to the failure of treatment of life-threatening 
bacterial infections and increases costs due to longer 
stay in healthcare settings [23, 24]. The use of non-con-
ventional therapy to which bacteria are improbably to 
develop resistance, would be the best alternative. AgNPs 
are potential antimicrobials agents, which can be con-
sidered as an alternative to antibiotics for the treatment 
of infections caused by MDR bacteria [5]. AgNPs have 
been shown to possess strong and broad-spectrum anti-
microbial activity due to a combined effect between 




Fig. 3 Combination of AgNPs, blue light, and azithromycin against two isolates of MRSA. The triple combination of AgNPs with the blue light and 
azithromycin against two isolates of MRSA was assessed. The isolates were selected on the basis of synergistic response in checkerboard assay. 
Based on the best result of the combination in the checkerboard assay, the concentrations of the two agents were used as follow: a Isolate C41: 
AgNPs at 1/16 of the MIC, and azithromycin at 2 µg/mL. b Isolate N8: AgNPs at 1/16 of the MIC, and azithromycin at 0.25 µg/mL. AgNPs silver nano‑
particles, CFU colony forming unit, AZM azithromycin, SD standard deviation
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Methicillin-resistant S. aureus was used as a model 
in our study to assess the efficiency of combination of 
AgNPs, blue light, and anti-staphylococcal antibiotics. 
The isolates had been collected from different hospital 
units to guarantee the most possible representation of 
the Egyptian genotype population of S. aureus. We have 
previously found that members of CC8 are the prevail-
ing MRSA clone in Egypt (Unpublished data, Mas-
ter Thesis, Moussa et  al. 2010). Infections caused by 
S. aureus are among the most frequent causes of both 
a
b
Fig. 4 Combination of AgNPs, blue light, and clarithromycin against two isolates of MRSA. The triple combination of AgNPs with the blue light and 
clarithromycin against two isolates of MRSA was assessed. The isolates were selected on the basis of synergistic response in checkerboard assay. 
Based on the best result of the combination in the checkerboard assay, the concentrations of the two agents were used as follow: a Isolate C51: 
AgNPs at 1/8 of the MIC, and azithromycin at 0.25 µg/mL. b Isolate C41: AgNPs at 1/512 of the MIC, and azithromycin at 0.25 µg/mL. AgNPs silver 
nanoparticles, CFU colony forming unit, CLR clarithromycin, SD standard deviation
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healthcare-associated and community-onset infections 
[26]. MRSA and coagulase-negative staphylococci are 
among the leading causes of nosocomial blood stream 
infections in the USA [27]. Staphylococci cause biofilm-
associated infections by forming biofilms on damaged 
tissues, and indwelling vascular catheters [28–32].
Five antibiotics were selected from different con-
ventional classes including beta-lactam (amoxicillin), 
macrolides (azithromycin and clarithromycin), oxazolidi-
nones (linezolid), and glycopeptides (vancomycin). Based 
on the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) MIC breakpoint guideline 
a
b
Fig. 5 Combination of AgNPs, blue light, and linezolid against two isolates of MRSA. The triple combination of AgNPs with the blue light and 
linezolid against two isolates of MRSA was assessed. The isolates were selected on the basis of synergistic response in checkerboard assay. Based 
on the best result of the combination in the checkerboard assay, the concentrations of the two agents were used as follow: a Isolate C19: AgNPs at 
1/2 of the MIC, and azithromycin at 0.25 µg/mL. b Isolate N5: AgNPs at 1/2 of the MIC, and azithromycin at 8 µg/mL. AgNPs silver nanoparticles, CFU 
colony forming unit, LNZ linezolid, SD standard deviation
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[33], all isolates were found to be resistant to amoxicil-
lin, azithromycin, clarithromycin, and linezolid, while 
they were susceptible to vancomycin (Table  2). With 
few exceptions, MRSA isolates are resistant to all beta-
lactam antibiotics and commonly resistant to macrolides, 
with very rare resistance to glycopeptides antibiotics [33, 
34]. Emergence of linezolid-resistance was previously 
reported in 0.05 % of S. aureus infections [35]. Antibiotics 
that are known to be ineffective against MRSA were used 
in this study to assess the possibility of enhancement of 
their antimicrobial activity by AgNPs and the blue light. 
This approach would be useful in “recycling” of these 
antibiotics that became useless against infections caused 
by MRSA to face the fast-growing drug-resistance with 
the slow development of new antimicrobial agents, and 
to preserve last resort antibiotics such as vancomycin.
Blue light has attracted increasing attention because of 
its intrinsic antimicrobial effect which does not involve 
the use of exogenous photosensitizers as in the pho-
todynamic therapy (PDT), and the less damaging to 
mammalian cells than ultraviolet irradiation [13]. The bio-
medical applications of blue light at specific wavelengths 
and intensities against different pathogens have been 
reported earlier [36]. At 470 nm blue light was found to be 
efficient against MRSA strains associated with hospital-
acquired and community-onset infections [37].
Double combinations of the AgNPs, at 1/2–1/128 of its 
MIC, with blue light were tested against selected MRSA 
isolates. The bactericidal activity of both agents was 
significantly enhanced (p  <  0.001) when bacteria were 
treated with AgNPs with concurrent exposure to blue 
light for 1 h, compared to each of them alone (Fig. 1a–e). 
The combined therapy killed all bacteria after 8  h in all 
tested combinations while each of the silver compound 
and the blue light was less efficient in killing the organ-
isms during the tested time. The mechanism of the anti-
microbial effect of either AgNPs or blue light is still not 
fully understood. Several hypotheses have been sug-
gested to explain such mechanisms. For example, it has 
been reported that AgNPs can damage bacterial cell 
membranes leading to structural changes, which render 
bacteria more permeable [38, 39]. AgNPs have unique 
optical, electrical, and thermal properties with high sur-
face area to volume ratio resulting in the optimal possi-
ble interaction with bacterial surfaces leading to a higher 
antimicrobial activity [40]. The formation of free radicals 
by the silver nanoparticles is probably another mecha-
nism that can lead to cell death [41, 42]. It has also been 
proposed that cationic silver is released from the nano-
particles when they are dissolved in water or when they 
penetrate into the cells [5]. Silver ions bind to the cel-
lular membranes, proteins, and nucleic acids, causing 
Fig. 6 Visualization of the effect of combination of AgNPs, blue light, and azithromycin on MRSA isolate N8 using transmission electron microscope 
(TEM). The antimicrobial efficacy of the AgNPs at 1/16 MIC, blue light and azithromycin at 0.25 µg/mL alone and in triple combination against 
isolate N8 was visualized by TEM at ×80,000. The photos show the response of the bacteria to the following treatments: a Drug‑free and light‑free 
(control). b AgNPs alone at 1/16 of its MIC. c Blue light exposure at 460 nm and 250 mW for 1 h. d Azithromycin alone at 0.25 µg/mL. e Triple combi‑
nation of AgNPs, blue light and the azithromycin. Signs of membrane damage and cell lysis were more pronounced in cells treated with a combina‑
tion of three agents compared to cells treated with each agent alone. Small arrows indicate the location of the AgNPs and the sites of the damage
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structural changes and deformations of the bacterial cell 
[5]. They also deactivate many vital enzymes by interac-
tion with thiol groups [31] and are involved in the gen-
eration of reactive oxygen species [32].
For blue light, the commonly accepted hypothesis is the 
production of highly cytotoxic reactive oxygen species 
(ROS) in a similar manner to PDT [43].
We have previously reported a similar synergistic inter-
action for a combination of AgNPs and blue light when 
both agents were tested against clinical isolates of Pseu-
domonas aeruginosa [44]. A possible mechanism of the 
observed synergy could be the transduction of the cap-
tured blue-light energy by blue light sensory proteins to 
the AgNPs resulting in the thermal destruction of the 
bacterial cells [45, 46].
Double combination of the AgNPs with five conven-
tional antibiotics against the ten MRSA clinical isolates 
was investigated using checkerboard assay. Synergistic 
interactions were observed when the AgNPs were used 
with amoxicillin, azithromycin, clarithromycin or line-
zolid in 30–40 % of the combinations (Fig. 2). Other com-
binational activities were indifferent with no observed 
antagonistic interaction. Combination of the AgNPs with 
vancomycin, on the other hand, was indifferent against 
all isolates. Synergistic interactions between AgNPs and 
conventional antibiotics against different pathogens were 
previously reported. Ruden et  al. [47] found synergistic 
interaction when AgNPs were combined with polymyxin 
B against gram-negative bacteria. Combination of AgNPs 
with ampicillin, chloramphenicol, and kanamycin against 
gram-positive and -negative pathogenic bacteria was also 
found to be synergistic [48]. Similarly, Smekalova et al. [49] 
observed synergistic effect when AgNPs were combined 
with penicillin G, gentamycin, and colistin against MDR 
bacteria.
Reversion of MRSA resistance to ineffective antibiot-
ics by combination with AgNPs could be a novel strategy 
to combat infections caused by MDR pathogens. Bio-
compatible gold nanoparticles-amoxicillin complex was 
found to overcome the resistance of MRSA to the anti-
biotic [50]. The synergistic response of combination of 
AgNPs and ineffective antibiotics is probably due to an 
increase of the concentration of antibiotics at the site of 
bacterium–antibiotic interaction, and to facilitate bind-
ing of antibiotics to bacteria [51].
AgNPs combined with amoxicillin, azithromycin, 
clarithromycin or linezolid were tested against selected 
MRSA isolates with concurrent exposure to blue light 
for 1  h. The isolates were selected based on synergistic 
response, where they were most affected by the previ-
ous double combinations in the checkerboard assay. The 
antimicrobial activity of the three agents was signifi-
cantly (p  >  0.001) enhanced in the triple combinations 
compared to single- and double treatments with one 
or two of them. The bactericidal activity was more pro-
nounced when azithromycin or clarithromycin was 
included in the triple therapy (Figs.  3, 4). The antimi-
crobial efficiency was also enhanced when linezolid 
(Fig.  5) or amoxicillin (data not shown) was included 
but with the same bactericidal effect in double and triple 
combinations.
The synergy observed in triple therapy might be 
explained by the combined mechanism of action of each 
agent alone, and the enhanced outcomes in their double 
combinations.
TEM images of isolate N8 that has been exposed to tri-
ple therapy (AgNPs, blue light and azithromycin) support 
the aforementioned suggestion that bacterial cell damage 
by the triple combination was more pronounced com-
pared to the cells that were treated with each agent alone 
(Fig. 6a–e).
Conclusions
This study suggests a new strategy to combat serious 
infections caused by MDR bacteria. The triple combina-
tion of AgNPs, blue light, and antibiotics is a promising 
therapy for infections caused by MRSA. The triple ther-
apy may include antibiotics, which are proven to be inef-
fective against MRSA. This approach would be useful to 
face the fast-growing drug-resistance with the slow devel-
opment of new antimicrobial agents, and to preserve last 
resort antibiotics such as vancomycin. The study can be 
taken further by exploring the application of the triple 
therapy in patients infected with MRSA and other MDR 
bacteria, taking into consideration the best conditions for 
optimizing their synergistic effects and decreasing the 
harmful side effect.
Abbreviations
AgNPs: silver nano particles; AMX: amoxicillin; AZM: azithromycin; CFU/mL: 
colony forming units per milliliter; CLR: clarithromycin; CLSI: Clinical Laboratory 
Standard Institute; EUCAST: European Committee on Antimicrobial Suscep‑
tibility Testing; FIC: Fraction Inhibitory Index; LNZ: linezolid; MBC: minimum 
bactericidal concentration; MDR: multi‑drug resistant; MHB: Mueller Hinton 
Broth; MIC: minimum inhibitory concentration; MLST: multiple locus sequence 
typing; MRSA: methicillin‑resistant Staphylococcus aureus; mg/L: milligram 
per liter; mW: milliwatt; OXA: oxacillin; PDT: photodynamic therapy; PVP: 
polyvinylpyrrolidone; ROS: reactive oxygen species; TEM: transmission electron 
microscope; VAN: vancomycin.
Authors’ contributions
FA performed the experimental work; TE prepared the nanomaterials, KA 
analyzed the results, guided FA for the experimental work and revised the final 
manuscript, ME designed the experiments, guided FA for the experimental 
work, generating the first draft, and finalized the manuscript. All authors read 
and approved the final manuscript.
Author details
1 Department of Microbiology, Immunology, and Biotechnology, German Uni‑
versity in Cairo, GUC, New Cairo City, Cairo, Egypt. 2 National Institute for Laser 
Enhanced Sciences, Cairo University, Cairo, Egypt. 
Page 12 of 13Akram et al. Ann Clin Microbiol Antimicrob  (2016) 15:48 
Competing interests
The authors declare that they have no competing interests.
The authors declare that they did not have any funding source or grant to 
support their research work.
The authors declare that the research work has been approved by their 
university ethics committees, although it doesn’t involve human subject or 
samples.
Received: 15 February 2016   Accepted: 5 August 2016
References
 1. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the 
antibiotic era. Nat Rev Microbiol. 2009;7(9):629–41.
 2. Franklin DL. Antimicrobial resistance: the example of Staphylococcus 
aureus. J Clin Invest. 2003;111(9):1265–73.
 3. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The 
evolutionary history of methicillin‑resistant Staphylococcus aureus (MRSA). 
Proc Natl Acad Sci USA. 2002;99(11):7687–92.
 4. Lara HH, Garza‑Treviño EN, Ixtepan‑Turrent L, Singh DK. Silver nano‑
particles are broad‑spectrum bactericidal and virucidal compounds. J 
Nanobiotechnology. 2011;9:30.
 5. Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, Galdiero 
M. Silver nanoparticles as potential antibacterial agents. Molecules. 
2015;20:8856–74.
 6. Nowack B, Krug H, Height M. 120 years of nanosilver history: 609 implica‑
tions for policy makers. Environ Sci Technol. 2011;45(4):1177–83.
 7. Bogumiła R, Andrea H, Andreas L, Kenneth AD, Iseult L. Mechanisms of 
silver nanoparticle release, transformation and toxicity: a critical review of 
current knowledge and recommendations for future studies and applica‑
tions. Materials. 2013;6:2295–350.
 8. Ansari M, Khan H, Khan A, Malik A, Sultan A, Shahid M, et al. Evaluation of 
antibacterial activity of silver nanoparticles against MSSA and MRSA on 
isolates from skin infections. Biol Med. 2011;3(2):141–6.
 9. Paredes D, Ortiz C, Torres R. Synthesis, characterization, and evaluation of 
antibacterial effect of Ag nanoparticles against Escherichia coli O157:H7 
and methicillin‑resistant Staphylococcus aureus (MRSA). Int J Nanomedi‑
cine. 2014;9:1717–29.
 10. Abdel Rahim KA, Mohamed AM. Bactericidal and antibiotic synergistic 
effect of nanosilver against methicillin‑resistant Staphylococcus aureus. 
Jundishapur J Microbiol. 2015;8(11):e25867.
 11. Vrcek IV, Zuntar I, Petlevski R, Pavicic I, Dutour SM, Culin M, et al. Compari‑
son of in vitro toxicity of silver ions and silver nanoparticles on human 
hepatoma cells. Environ Toxicol. 2016;31(6):679–92.
 12. D’Britto V, Kapse H, Babrekar H, Pabhune AA, Bhoraskar SV, Premnath V, 
et al. Silver nanoparticle studded porous polyethylene scaffolds: bacteria 
struggle to grow on them while mammalian cells thrive. Nanoscale. 
2011;3(7):2957–63.
 13. Tianhong D, Asheesh G, Clinton KM, Mark SV, George PT, Michael RH. Blue 
light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, 
and beyond. Drug Resist Updat. 2012;15(4):223–36.
 14. Maclean M, McKenzie K, Anderson JG, Gettinby G, MacGregor SJ. 405 
nm light technology for the inactivation of pathogens and its potential 
role for environmental disinfection and infection control. J Hosp Infect. 
2014;88(1):1–11.
 15. Enwemeka CS, Williams D, Enwemeka SK, Hollosi S, Yens D. Blue 470‑nm 
light kills methicillin‑resistant Staphylococcus aureus (MRSA) in vitro. 
Photomed Laser Surg. 2009;27(2):221–6.
 16. Halstead FD, Thwaite JE, Burt R, Laws TR, Raguse M, Moeller R, et al. 
Antibacterial activity of blue light against nosocomial wound pathogens 
growing planktonically and as mature biofilms. Appl Environ Microbiol. 
2016;82(13):4006–40016.
 17. Jonas D, Grundmann H, Hartung D, Daschner FD, Towner KJ. Evaluation 
of the mecA femB duplex polymerase chain reaction for detection of 
methicillin resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 
1999;18(9):643–7.
 18. Kapoor S. Preparation, characterization, and surface modification of silver 
particles. Langmuir. 1998;14(5):1021–5.
 19. Clinical and Laboratory Standards Institute (CLSI): methods for dilution 
antimicrobial susceptibility tests for bacteria that grow aerobically—
approved standards‑seventh edition, in CLSI document M7‑A7 2002, vol. 
26 No. 2, Pennsylvania. p. 16–18.
 20. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta‑lactam antibiotic 
therapy in febrile granulocytopenic patients. A randomized trial compar‑
ing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and 
imipenem alone. Ann Intern Med. 1991;115(11):849–59.
 21. Dykstra MJ, Reuss E. Biological electron microscopy theory, techniques 
and troubleshooting. 2nd ed. Berlin: Springer; 2003.
 22. Gould SW, Cuschieri P, Rollason J, Hilton AC, Easmon S, Fielder MD. The 
need for continued monitoring of antibiotic resistance patterns in clinical 
isolates of Staphylococcus aureus from London and Malta. Ann Clin Micro‑
biol Antimicrob. 2010;9:20.
 23. Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como‑Sabetti K, 
et al. Excess costs and utilization associated with methicillin resistance 
for patients with Staphylococcus aureus infection. Infect Control Hosp 
Epidemiol. 2010;31(4):365–73.
 24. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable 
hospital cost and length of stay associated with healthcare‑associated 
infections caused by antibiotic‑resistant gram‑negative bacteria. Antimi‑
crob Agents Chemother. 2010;54(1):109–15.
 25. Choi O, Hu Z. Size dependent and reactive oxygen species related 
nanosilver toxicity to nitrifying bacteria. Environ Sci Technol. 
2008;42:4583–8.
 26. von Eiff C, Heilmann C, Herrmann M, Peters G. Basic aspects of the 
pathogenesis of staphylococcal polymer associated infections. Infection. 
1999;27(Suppl 1):S7–10.
 27. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520–32.
 28. Khardori N, Yassien M, Wilson K. Tolerance of Staphylococcus epidermidis 
grown from indwelling vascular catheters to antimicrobial agents. J Ind 
Microbiol. 1995;15:148–51.
 29. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents. 
1999;11:217–21.
 30. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common 
cause of persistent infections. Science. 1999;284(5418):1318–22.
 31. Gross M, Cramton SE, Götz F, Peschel A. Key role of teichoic acid net 
charge in Staphylococcus aureus colonization of artificial surfaces. Infect 
Immun. 2001;69:3423–6.
 32. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically 
relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93.
 33. The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST): breakpoint tables for interpretation of MICs and zone diam‑
eters. Version 5.0. 2015. http://www.eucast.org. Accessed 3 Nov 2015
 34. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA. Participants in the CDC 
convened experts meeting on management of MRSA in the community. 
strategies for clinical management of MRSA in the community: summary 
of an experts’ meeting convened by the centers for disease control and 
prevention. 2006.
 35. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging 
problem of linezolid‑resistant Staphylococcus. J Antimicrob Chemother. 
2013;68(1):4–11.
 36. Guffey JS, Wilborn J. Effects of combined 405‑nm and 880‑nm light on 
Staphylococcus aureus and Pseudomonas aeruginosa in vitro. Photomed 
Laser Surg. 2006;24(6):680–3.
 37. Enwemeka CS, Williams D, Enwemeka SK, Hollosi S, Yens D. Blue 470‑nm 
light kills methicillin‑resistant Staphylococcus aureus (MRSA) in vitro. 
Photomed Laser Surg. 2008;27(2):221–6.
 38. Lazar V. Quorum sensing in biofilms—how to destroy the bacterial cita‑
dels or their cohesion power? Anaerobe. 2011;17:280–5.
 39. Periasamy S, Joo HS, Duong AC, Bach TH, Tan VY, Chatterjee SS, et al. How 
Staphylococcus aureus biofilms develop their characteristic structure. Proc 
Natl Acad Sci USA. 2012;109:1281–6.
 40. Morones JR, Elechiguerra JL, Camacho A, Ramirez JT. The bactericidal 
effect of silver nanoparticles. Nanotechnology. 2005;16:2346.
 41. Danilcauk M, Lund A, Saldo J, Yamada H, Michalik J. Conduction electron 
spin resonance of small silver particles. Spectrochim Acta Part A Mol 
Biomol Spectrosc. 2006;63:189–91.
Page 13 of 13Akram et al. Ann Clin Microbiol Antimicrob  (2016) 15:48 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 42. Kim JS, Kuk E, Yu K, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of 
silver nanoparticles. Nanomedicine. 2007;3:95–101.
 43. Maclean M, Macgregor SJ, Anderson JG, Woolsey GA. The role of oxygen 
in the visible‑light inactivation of Staphylococcus aureus. J Photochem 
Photobiol B. 2008;92(3):180–4.
 44. Nour ES, El‑Tayeb TA, Abou‑Aisha K, El‑Azizi M. In vitro and in vivo 
antimicrobial activity of combined therapy of silver nanoparticles and 
visible blue light against Pseudomonas aeruginosa. Int J Nanomedicine. 
2016;11:1749–58.
 45. Wu L, McGrane RS, Beattie GA. Light regulation of swarming motility 
in Pseudomonas syringae integrates signaling pathways mediated by a 
bacteriophytochrome and a LOV protein. MBio. 2013;4(3):e00334.
 46. Barkovits K, Schubert B, Heine S, Scheer M, Frankenberg‑Dinkel N. 
Function of the bacteriophytochrome BphP in the RpoS/Las quorum 
sensing network of Pseudomonas aeruginosa. Microbiology. 2011;157(Pt 
6):1651–64.
 47. Ruden S, Hilpert K, Berditsch M, Wadhwani P, Ulrich AS. Synergistic inter‑
action between silver nanoparticles and membrane‑permeabilizing anti‑
microbial peptides. Antimicrob Agents Chemother. 2009;53(8):3538–40.
 48. Hwang IS, Hwang JH, Choi H, Kim KJ, Lee DG. Synergistic effects between 
silver nanoparticles and antibiotics and the mechanisms involved. J Med 
Microbiol. 2012;61:1719–26.
 49. Smekalova M, Aragon V, Panacek A, Prucek R, Zboril R, Kvitek L. Enhanced 
antibacterial effect of antibiotics in combination with silver nanoparticles 
against animal pathogens. Vet J. 2015;209:174–9.
 50. Kalita S, Kandimalla R, Sharma KK, Kataki AC, Deka M, Kotoky J. Amoxicillin 
functionalized gold nanoparticles reverts MRSA resistance. Mater Sci Eng 
C Mater Biol Appl. 2016;61:720–7.
 51. Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. 
Coping with antibiotic resistance: combining nanoparticles with 
antibiotics and other antimicrobial agents. Expert Rev Anti Infect Ther. 
2011;9(11):1035–52.
